#1 Clinical Trials Search in Europe

Tezacaftor

Tezacaftor is a promising drug being studied in clinical trials for the treatment of cystic fibrosis (CF). As part of combination therapies with other CF medications, tezacaftor aims to improve lung function and quality of life for people with specific CF genetic mutations. This article explores the ongoing research into tezacaftor’s effectiveness and safety for CF patients.

Table of Contents

What is Tezacaftor?

Tezacaftor is a medication used in the treatment of cystic fibrosis (CF), a genetic disorder that affects the lungs and other organs. It is often referred to by its other names, including VX-661[3]. Tezacaftor is part of a class of drugs called CFTR modulators, which are designed to improve the function of the faulty protein responsible for CF[2].

How Tezacaftor Works

Tezacaftor works by helping the defective CFTR protein reach the cell surface and function more effectively. In cystic fibrosis, the CFTR protein is either missing or doesn’t work properly, leading to thick, sticky mucus in various organs. By improving CFTR function, tezacaftor helps to thin this mucus, potentially reducing symptoms and complications of CF[4].

Combination Therapy with Ivacaftor

Tezacaftor is typically used in combination with another medication called ivacaftor. This combination is known by various names, including:

  • Tezacaftor/Ivacaftor (TEZ/IVA)[1]
  • VX-661/VX-770[5]

The combination of tezacaftor and ivacaftor works better than either medication alone. While tezacaftor helps the CFTR protein reach the cell surface, ivacaftor helps the protein function better once it’s there[3].

Effectiveness of Tezacaftor

Clinical trials have shown that tezacaftor, when used in combination with ivacaftor, can provide several benefits for people with cystic fibrosis:

  • Improved lung function: Studies have shown an increase in FEV1 (a measure of how much air a person can exhale in one second) in patients taking tezacaftor/ivacaftor[3].
  • Reduced pulmonary exacerbations: These are periods when CF symptoms worsen, often requiring hospitalization. Tezacaftor/ivacaftor has been shown to decrease the frequency of these events[2].
  • Improved quality of life: Patients have reported improvements in respiratory symptoms and overall quality of life when taking this medication[3].

Potential Side Effects

As with all medications, tezacaftor can cause side effects. Common side effects reported in clinical trials include:

  • Headache
  • Nausea
  • Sinus congestion
  • Dizziness

It’s important to discuss any side effects with your healthcare provider. They can help determine if the benefits of the medication outweigh any potential risks[5].

Ongoing Research

Research on tezacaftor and its combinations continues. Scientists are studying its effects on various aspects of CF, including:

  • Lung imaging: Researchers are using low-dose computed tomography (LDCT) to see how tezacaftor/ivacaftor affects the structure of the lungs over time[5].
  • Sinus disease: Studies are looking at how this medication impacts CF-related sinus problems[6].
  • Growth and development: There’s ongoing research into how tezacaftor and similar medications affect growth in children with CF[7].
  • Glucose tolerance: Researchers are investigating how tezacaftor and related medications might affect glucose tolerance and diabetes risk in people with CF[8].

These ongoing studies will help us better understand the full potential of tezacaftor in treating cystic fibrosis and may lead to improved treatments in the future.

Aspect Details
Drug Name Tezacaftor (often used in combination with ivacaftor)
Target Condition Cystic Fibrosis
Mechanism of Action CFTR corrector, improves processing and function of defective CFTR protein
Patient Population CF patients with specific genetic mutations, especially F508del
Administration Oral, typically as combination therapy
Primary Outcomes Studied Lung function (FEV1), sweat chloride levels, quality of life measures
Secondary Outcomes Pulmonary exacerbations, nutritional status, safety profile
Ongoing Research Focus Long-term efficacy, effects in different age groups, impact on various CF symptoms

FAQ

  • What is tezacaftor and how does it work? Tezacaftor is a CFTR corrector that helps improve the processing and function of the defective CFTR protein in cystic fibrosis. It is typically used in combination with other CF medications like ivacaftor to enhance its effects.
  • Who can benefit from tezacaftor treatment? Tezacaftor is being studied for CF patients with specific genetic mutations, particularly those who are homozygous for the F508del-CFTR mutation or have one F508del mutation and a second mutation that responds to CFTR modulators.
  • What are the potential benefits of tezacaftor treatment? Clinical trials are investigating if tezacaftor combination therapy can improve lung function, reduce pulmonary exacerbations, enhance quality of life, and positively impact other aspects of CF like nutritional status.
  • How is tezacaftor administered? Tezacaftor is typically given orally in combination with other CF medications. For example, one regimen being studied is a fixed-dose combination tablet of tezacaftor/ivacaftor taken once daily in the morning and an ivacaftor tablet taken in the evening.
  • What are researchers still trying to learn about tezacaftor? Ongoing studies aim to better understand tezacaftor's long-term safety and efficacy, its effects on different age groups including young children, and its impact on various CF symptoms beyond just lung function.

Ongoing Clinical Trials on Tezacaftor

  • Study of VX-121, Tezacaftor, and Deutivacaftor for Children Aged 1-11 with Cystic Fibrosis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany The Netherlands Sweden

  • Study on Long-Term Safety and Effectiveness of Vanzacaftor, Tezacaftor, and Deutivacaftor for Cystic Fibrosis in Patients Aged 1 Year and Older

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany The Netherlands Sweden

  • Safety and Efficacy of VX-828, Deutivacaftor, and Tezacaftor in Adults with Cystic Fibrosis

    Not yet recruiting

    1 1
    Investigated drugs:
    Belgium Czechia Denmark France Germany Ireland +5

  • Study of elexacaftor, tezacaftor and ivacaftor combination therapy to evaluate blood levels in patients with Cystic Fibrosis

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Long-term Safety and Efficacy of Elexacaftor, Tezacaftor, and Ivacaftor in Children and Adults with Cystic Fibrosis Aged 2 Years and Older

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Safety and Tolerability of Elexacaftor, Tezacaftor, and Ivacaftor in Children with Cystic Fibrosis Aged 12 to Less Than 24 Months

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Germany The Netherlands

  • Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +10

  • Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Hungary +7

  • Study on Long-term Safety and Efficacy of Elexacaftor, Tezacaftor, and Ivacaftor for Cystic Fibrosis in Patients Aged 12 Months and Older

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Germany The Netherlands

Glossary

  • CFTR: Cystic Fibrosis Transmembrane Conductance Regulator, the protein that is defective in cystic fibrosis.
  • F508del mutation: The most common genetic mutation causing cystic fibrosis, where the CFTR protein is missing an amino acid.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function often used to assess CF severity and treatment effects.
  • Pulmonary exacerbation: A worsening of respiratory symptoms in CF patients, often requiring additional treatment.
  • Sweat chloride test: A diagnostic test for CF that measures the amount of chloride in a person's sweat.
  • CFTR modulator: A type of medication that aims to improve the function of the defective CFTR protein in cystic fibrosis.
  • Ivacaftor: Another CF medication often used in combination with tezacaftor to enhance CFTR function.
  • Percent predicted FEV1: A way of expressing lung function as a percentage of what would be expected in a healthy person of similar age, height, and gender.
  • Quality of life (QOL): A measure of a person's overall wellbeing and ability to function in daily life, often assessed in CF clinical trials.
  • Mucociliary clearance: The process by which the lungs clear mucus, which is often impaired in CF patients.

References

  1. https://clinicaltrials.gov/study/NCT03278314
  2. https://clinicaltrials.gov/study/NCT05576324
  3. https://clinicaltrials.gov/study/NCT02412111
  4. https://clinicaltrials.gov/study/NCT02508207
  5. https://clinicaltrials.gov/study/NCT02730208
  6. https://clinicaltrials.gov/study/NCT04056702
  7. https://clinicaltrials.gov/study/NCT04509050
  8. https://clinicaltrials.gov/study/NCT06331000